Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis

• James D. Chalmers,
• Mark L. Metersky,
• Joseph Feliciano,
• Carlos Fernandez,
• Ariel Teper,
• Andrea Maes,
• Mariam Hassan,
• Anjan Chatterjee

Affiliations

James D. Chalmers

Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

Mark L. Metersky

University of Connecticut School of Medicine, Farmington, CT, USA

Joseph Feliciano

Insmed Incorporated, Bridgewater, NJ, USA

Carlos Fernandez

Insmed Incorporated, Bridgewater, NJ, USA

Ariel Teper

Insmed Incorporated, Bridgewater, NJ, USA

Andrea Maes

Insmed Incorporated, Bridgewater, NJ, USA

Mariam Hassan

Insmed Incorporated, Bridgewater, NJ, USA

Anjan Chatterjee

Insmed Incorporated, Bridgewater, NJ, USA